Research progress of sacubitril/valsartan in heart failure

As an innovative drug in the field of chronic heart failure treatment worldwide in recent years, sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan. In the PARADIGM-HF trial, sacubitril/valsartan significantly reduced the primary endpoint of cardiovascular mortality and heart failure hospitalization, compared with enalapril. The rate of all-cause mortality was also significantly reduced. Subsequently, the European Society of Cardiology and American College of Cardiology/American Heart Association/Heart Failure Society of America recently have updated guideline recommendations for heart failure with reduced ejection fraction to recommend sacubitril/valsartan. This manuscript reviews new research of sacubitril/valsartan in heart failure.